| Phase 01 trial |
|
Phase 0
|
NCT06959563 |
Apr 2025 → Oct 2026 expected |
human papilloma virus infection |
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair |
Active not recruiting
|
No outcome recorded
|
| Phase 39 trials · 1 met primary |
|
Phase 3
|
NCT05450705 |
Jul 2022 → Aug 2029 expected |
human papilloma virus infection |
Merck Sharp & Dohme LLC |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05314023 |
May 2022 → Feb 2029 expected |
anogenital human papillomavirus infection |
Merck Sharp & Dohme LLC |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05119855 |
Mar 2022 → Dec 2023 |
COVID-19, human papilloma virus infection |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT05285826 |
Feb 2022 → May 2029 expected |
human papilloma virus infection |
Merck Sharp & Dohme LLC |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT04772534 |
May 2021 → Apr 2024 |
human papilloma virus infection |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT04313244 |
May 2021 → Feb 2022 |
dengue disease |
Takeda |
Completed
|
Met primary
|
|
Phase 3
|
NCT04708041 |
Mar 2021 → Oct 2029 expected |
human papilloma virus infection |
Merck Sharp & Dohme LLC |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT04199689 |
Feb 2020 → Aug 2027 expected |
human papilloma virus infection |
Merck Sharp & Dohme LLC |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT03546842 |
Jun 2018 → Jan 2019 |
adenocarcinoma in situ, anogenital human papillomavirus infection, uterine cervix neoplasm, vaginal neoplasm +1 |
Merck Sharp & Dohme LLC |
Completed
|
No outcome recorded
|